The FDA's Molecular and Clinical Genetics Panel voted on September 23, 2026, in support of GRAIL's premarket approval (PMA) application for the Galleri multicancer early detection (MCED) test — the first MCED test to reach this regulatory stage. Galleri works by detecting cancer-specific DNA methylation patterns in cell-free blood DNA and can flag signals for more than 50 cancer types, including many with no existing screening options (e.g., pancreatic, esophageal, and ovarian cancers). The FDA is not required to follow the panel's recommendation, but typically does; a final approval decision is expected in the coming months.

Despite the favorable votes, significant uncertainty remains. The landmark NHS-Galleri randomized trial — involving over 142,000 adults — failed to meet its primary endpoint of reducing stage III/IV cancer diagnoses. Across both major studies, the test missed more than half of all cancers, and no data yet show that testing leads to longer or better lives.

Key Takeaways:

• Panel votes: Safety 10–0; Effectiveness 6–4; Benefits outweigh risks 7–2 (1 abstention)
• Sensitivity was ~35% overall but rose to ~70% for 12 cancers responsible for most U.S. cancer deaths
• Roughly 4 in 10 "cancer signal detected" results were false positives in PATHFINDER 2
• If approved, Medicare coverage could begin as early as January 1, 2029, under the Nancy Gardner Sewell Act
• Clinicians should prepare three key conversations: managing a positive result workup, counseling that a negative result is not an all-clear, and discussing out-of-pocket costs upfront

Why it matters: Galleri's FDA advisory win is a watershed moment for cancer screening, potentially expanding detection to cancers that currently have no early-warning options. But with no mortality benefit proven yet, clinicians must be ready to guide patients through nuanced, high-stakes conversations about what this test can — and cannot — tell them.